Caricamento...
Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation
FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) are exquisitely sensitive to imatinib. Almost all patients achieve a complete molecular remission (CMR) by nested reverse transcription polymerase chain reaction, which can be maintained with low-dose imatinib (eg, 3 × 100...
Salvato in:
| Pubblicato in: | Blood Adv |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Hematology
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7013256/ https://ncbi.nlm.nih.gov/pubmed/31995156 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001111 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|